Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: SillaJen CEO Confident On ‘Dream’ Cancer Therapy (Pt. 2)

This article was originally published in PharmAsia News

Executive Summary

After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO, Moon Eun-sang, shares his views on the product and SillaJen’s future in this second and final part of an exclusive interview with PharmAsia News.

You may also be interested in...

Amgen T-VEC’s Remaining Challenges: Getting To Market, Staying Relevant

After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.

HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line

HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.

Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM

Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts